Vascular endothelial growth factor trap in non small cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Vascular Endothelial Growth Factor (VEGF) pathway is a validated target for non-small cell lung cancer (NSCLC) treatment.
• Current therapies include bevacizumab (anti-VEGF antibody) and small-molecule VEGF receptor (VEGFR) tyrosine kinase inhibitors.
• VEGF Trap is an engineered soluble receptor targeting VEGF isoforms and placental growth factor.

Purpose of the Study:

• To evaluate the safety and efficacy of VEGF Trap in NSCLC treatment.
• To compare the binding affinity of VEGF Trap with bevacizumab.
• To explore combinations of VEGF Trap with standard chemotherapy regimens.

Main Methods:

• Phase I trials of subcutaneous (s.c.) and intravenous (i.v.) VEGF Trap administration.
• Assessment of toxicities including hypertension and proteinuria.
• Radiographic evaluation in a heavily pretreated NSCLC patient.
• Ongoing Phase I trials combining VEGF Trap with platinum-based doublets and docetaxel.
• Multicenter Phase II trial assessing single-agent VEGF Trap activity in NSCLC.

Main Results:

• VEGF Trap exhibits higher binding affinity for VEGF-A and VEGF-B compared to bevacizumab.
• Observed toxicities (hypertension, proteinuria) are consistent with VEGF pathway inhibition.
• A patient with heavily pretreated NSCLC showed significant radiographic improvement in a Phase I trial.

Conclusions:

• VEGF Trap demonstrates a potentially favorable safety profile and preliminary efficacy in NSCLC.
• Further clinical trials are warranted to establish its role in NSCLC therapy, including combination strategies.